Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Xiaomei Bian"'
Autor:
Yuan Chen, Su Liang, Xiuqing Gao, Sunil Krishnan, Pankaj Singh, Oscar Ekpenyong, Huan Xie, Jon A. Schwartz, Jing Ma, Maureen Aliru, Jyothy John, Yuanqing Ye, Amit Deorukhkar, Xiaomei Bian
Publikováno v:
Oncotarget
Tumor hypoxia is a well-recognized driver of resistance to traditional cancer therapies such as chemotherapy and radiation therapy. We describe development of a new nanoconstruct composed of gold nanorods (GNRs) conjugated to carbonic anhydrase IX (C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69c28fa860e6ba34bd28777707f76e92
https://doi.org/10.18632/oncotarget.25492
https://doi.org/10.18632/oncotarget.25492
Autor:
Xiaomei Bian, Sunil Krishnan, Amit Deorukhkar, Su Liang, Jing Ma, Motolani Arogunjo, Huan Xie
Publikováno v:
Biomedical Chromatography. 27:58-66
γ-Tocotrienol has attracted much attention owing to its multiple health benefits. This study developed and validated a simple, specific, sensitive and reliable LC/MS/MS method to analyze γ-tocotrienol in rat plasma. Plasma samples (50 μL) were ext
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9341ff2b81f5d96f05641e4ed035745e
https://doi.org/10.1002/bmc.2748
https://doi.org/10.1002/bmc.2748
Publikováno v:
American journal of modern chromatography. 1(1)
MJC13 is a novel molecule that has potential use for the treatment of hormone refractory prostate cancer (HRPC). The purpose of this work was to develop a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for quantification of MJC13. I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0a6d1f3357dc4a2a55bc620310aaf701
https://pubmed.ncbi.nlm.nih.gov/25594071
https://pubmed.ncbi.nlm.nih.gov/25594071
Autor:
Leonard M. Neckers, Dong Liang, Jeffrey C. Sivils, Xiaomei Bian, Huan Xie, Su Liang, Marc B. Cox
Publikováno v:
Pharmaceutical development and technology. 21(1)
MJC13, a novel FKBP52 targeting agent, has potential use for the treatment of castration-resistant prostate cancer. The purpose of this work was to develop a solution formulation of MJC13, and obtain its efficacy profile in a human prostate cancer xe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a90c603ac140ad7d1a16dbda526b36f
https://pubmed.ncbi.nlm.nih.gov/25380396
https://pubmed.ncbi.nlm.nih.gov/25380396
Publikováno v:
International Journal of Nanomedicine
Xiaomei Bian,1 Su Liang,1 Jyothy John,1 Cheng-Hui Hsiao,1 Xin Wei,2 Dong Liang,1 Huan Xie1 1Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, 2Department of Chemistry, College of Science and Technology, Texas Southern Un
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b132cfbfad18815cad5e63a7d403667
https://doi.org/10.2147/ijn.s54040
https://doi.org/10.2147/ijn.s54040
Publikováno v:
Cancer Research. 72:2889-2889
PURPOSE: Hypoxia is a common feature of solid tumors that occurs across a wide variety of malignancies and significantly reduces tumor sensitivity to radiation and chemotherapy. Carbonic anhydrase IX (CAIX), an extracellular protein that is overexpre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::98550a4167460be14e10b22c3076762c
https://doi.org/10.1158/1538-7445.am2012-2889
https://doi.org/10.1158/1538-7445.am2012-2889
Publikováno v:
International Journal of Nanomedicine; 2013, Vol. 9, p4521-4531, 11p